Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2009

View Archived Issues

Novel antibiotics synthesized at Cubist Pharmaceuticals

Phase II data support further development of EndoTAG/gemcitabine in pancreatic cancer

Vandetanib fails to meet primary endpoint in phase II trial in HCC patients

PK/PD data on the GLP-1 receptor agonist AVE-0010 presented at recent EASD meeting

INCB-13739 added to metformin improves HbA1c and LDL-C in type 2 diabetes patients

BI-10773 exhibits promising preclinical antidiabetic activity in rodent models

Novel 5-HT2C receptor agonist PF-3246799 shows favorable activity in animal models

Helix BioPharma presents update on development of topical interferon alpha-2b and L-DOS-47

Merz reports results from phase III study of NT-201 in post-stroke upper limb spasticity

Quest Diagnostics initiates DNA testing for Plavix response in coronary heart patients

Epigenomics launches Epi proColon blood test for early detection of colorectal cancer

Keryx initiates phase II perifosine study in CLL and SLL

Cipher begins enrollment in phase III CIP-Isotretinoin trial in severe nodular acne

Promising preclinical data support TRK-380 as a novel candidate for OAB treatment

Antisoma to amend primary endpoint of phase III trial of AS-1413 in AML

Relypsa initiates enrollment in phase IIb trial of RLY-5016 for hyperkalemia

Sanofi pasteur reports results from studies of Panenza and Humenza vaccines

IDEA reports results from two phase III studies of Diractin for osteoarthritis of the knee

Novartis gains exclusive worldwide rights to broad-spectrum PTK-0796 antibiotic from Paratek

European Commission approves Baxter's Celvapan H1N1 pandemic influenza vaccine

Cellceutix reports results of KM-133 study in human xenograft mouse model of psoriasis

Nymox reports results from phase II clinical trial of NX-1207 for BPH

FDA approves Daiichi Sankyo's sNDA for Welchol in pediatric patients with heFH

Novel antibacterial agents described by LEAD Therapeutics

Novel Jak2 inhibitors disclosed by Rigel for the treatment of cancer

Muscarinic M3 receptor antagonists claimed by AstraZeneca and Argenta Discovery

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...